Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the following hypothesis: Patients with metastatic castrate
resistant prostate cancer that have progressed following at least one line of therapy and
have an immunogenic signature will respond to combined PD-1 and CTLA4 inhibition.